ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05116748 (Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation), which is not on this map. Cited by 158 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation (Lung and / or Liver) Adult Recipients
Who cites it
158 citing papers in PubMed, 6 syntheses or guidelines pooled it, 405 citations in OpenAlex.
- [Vaccination of immunocompromised individuals: Expert opinion - update 2026].Wiener klinische Wochenschrift · 2026Guideline
- Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.PharmacoEconomics - open · 2026Pooled it
- Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future.Transplant international : official journal of the European Society for Organ Transplantation · 2025Pooled it
- Donor heart selection: Evidence-based guidelines for providers.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2023Guideline
- COVID-19 and solid organ transplantation: Finding the right balance.Transplantation reviews (Orlando, Fla.) · 2022Pooled it
- Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression.Frontiers in endocrinology · 2022Pooled it
- Recent perioperative challenges in anesthesia during expansion of heart transplantation.Journal of cardiothoracic surgery · 2026Review
- Article
- SARS-CoV-2 infection in lung transplant recipients: a single-center retrospective study in Japan.Surgery today · 2026Article
- Impact of COVID-19 vaccination on long-Term patient and kidney allograft survival following SARS-CoV-2 infection.medRxiv : the preprint server for health sciences · 2026Article
- Prognosis of patients with a history of organ transplantation during active COVID-19 infection.BMC infectious diseases · 2025Article
- Respiratory viral infections in lung transplantation: Recent advances in epidemiology, clinical impact, and therapeutic approaches.JHLT open · 2025Article
- A Single-Center Retrospective Study on Early Treatment for COVID-19 in Solid Organ Transplant Recipients During the Omicron Era: Outcomes and SARS-CoV-2 Viral Kinetics.Microorganisms · 2025Article
- Anxiety and Depressive Symptoms Post-COVID-19 Pandemic Onset in Solid Organ Transplant Recipients: Canadian Repeated Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Systems vaccinology identifies immunological correlates of SARS-CoV-2 vaccine response in solid organ transplant recipients.NPJ vaccines · 2025Article
- Risk factors for mortality among kidney transplant recipients with COVID-19 in Saudi Arabia: a case-control study.BMC infectious diseases · 2025Article
- Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients.Cell reports. Medicine · 2025Article
- Vaccines for Use in Special Populations: Immunocompromised Hosts.The Journal of infectious diseases · 2025Article
- Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients.Nature communications · 2025Article
- Risk factor analysis and outcomes of heart transplant recipients infected by COVID-19.Frontiers in immunology · 2025Observational
98 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
35 authors at 18 institutions in 2 countries.
Funding
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) pandemic has led to significant reductions in transplantation, motivated in part by concerns of disproportionately more severe disease among solid organ transplant (SOT) recipients. However, clinical features, outcomes, and predictors of mortality in SOT recipients are not well described.
methodsWe performed a multicenter cohort study of SOT recipients with laboratory-confirmed COVID-19. Data were collected using standardized intake and 28-day follow-up electronic case report forms. Multivariable logistic regression was used to identify risk factors for the primary endpoint, 28-day mortality, among hospitalized patients.
resultsFour hundred eighty-two SOT recipients from >50 transplant centers were included: 318 (66%) kidney or kidney/pancreas, 73 (15.1%) liver, 57 (11.8%) heart, and 30 (6.2%) lung. Median age was 58 (interquartile range [IQR] 46-57), median time post-transplant was 5 years (IQR 2-10), 61% were male, and 92% had ≥1 underlying comorbidity. Among those hospitalized (376 [78%]), 117 (31%) required mechanical ventilation, and 77 (20.5%) died by 28 days after diagnosis. Specific underlying comorbidities (age >65 [adjusted odds ratio [aOR] 3.0, 95% confidence interval [CI] 1.7-5.5, P < .001], congestive heart failure [aOR 3.2, 95% CI 1.4-7.0, P = .004], chronic lung disease [aOR 2.5, 95% CI 1.2-5.2, P = .018], obesity [aOR 1.9, 95% CI 1.0-3.4, P = .039]) and presenting findings (lymphopenia [aOR 1.9, 95% CI 1.1-3.5, P = .033], abnormal chest imaging [aOR 2.9, 95% CI 1.1-7.5, P = .027]) were independently associated with mortality. Multiple measures of immunosuppression intensity were not associated with mortality.
conclusionsMortality among SOT recipients hospitalized for COVID-19 was 20.5%. Age and underlying comorbidities rather than immunosuppression intensity-related measures were major drivers of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.